EGFR-TKI分子靶向治疗非小细胞肺癌的研究进展
摘要
肺癌是我国常见的恶性肿瘤之一,具有较高的发病率及死亡率,其占据恶性肿瘤首位。目前肺癌的治疗方案主要以手术,放疗,化疗为主,但对于晚期肺癌患者的治疗,现多采用靶向治疗为主,靶向治疗解决了除之前的传统治疗方法的空白,为更好的解决肺癌患者的疾病带来了新的治疗方法,但在临床带来获益的同时,发现靶向治疗在后期会出现耐药性,从而使靶向治疗带来了局限性,本文介绍了靶向治疗非小细胞肺癌的药物,耐药机制以及中医药联合治疗靶向治疗肺癌的研究现状。
引文
[1]钱彦方.中医药对肺癌临床干预的思考[J].现代中西医结合杂志,2011,20(33):4301.
[2]狄鸿胜.非小细胞肺癌的治疗新进展[J].吉林医学,2012,3(10):2165-2166.
[3]李新,韩峰,张小涛.等.NP方案联合同步调强放疗治疗局部晚期非小细胞肺癌的临床观察[J].中国肿瘤临床,2012,39(23):1964-1966.
[4]张力建,陈晋峰.非小细胞肺癌的综合治疗[J].中华肿瘤防治杂志,200612(23):232-4.
[5]支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,1:73-74.
[6]Ettinger DS,Wood DE,Akerley W.NCCN Guidelines Insights:Non-Small Cell Lung Cancer,Version4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-264.
[7]张妮,曾维威,张献全.培美曲塞维持治疗晚期非小细胞肺癌的Meta分析[J].中国老年学杂志,2014,34(07):1774-1776.
[8]田晓刚,王小虎.非小细胞肺癌放疗的研究进展[J].甘肃医药,2012,31(09):673-675.
[9]贺智勇,荣阳,荣根满.中晚期肺癌介入治疗的疗效分析与临床研究[J].中国医药指南,2017,15(19):138.
[10]张宁玲.肺癌分子靶向治疗分析[J].肿瘤药学,2012,2(2):151-153.
[11]Xu Y,Zhu C,Qian W,et al.Comprehensive study of mutational and clinicopathologiccharacteristicsofadenocarcinomawithlepidic pattern in surgical resected lung adenocarcinoma[J].J Cancer Res Clin Oncol,2017,143:181-186.
[12]IdbaihA,AimardJ,BoisselierB,etal.Epidermalgrowthfactor receptorextracellular domain mutations in primary glioblastoma[J].NeuropatholApp Neurobiol,2009,35(2):208-13.
[13]金静思,贺巾钊,周黎明.非小细胞肺癌分子靶向治疗药物的现状及进展[J].中国肿瘤临床,2015,42(17):881-885.
[14]梁琨,杨帆.吉非替尼一线治疗EGFR突变型非小细胞肺癌老年患者的临床研究[J].陕西医学杂志,2017,(12):1670-1671.
[15]袁刚,韩涛,刘中正,等.厄洛替尼治疗老年晚期非小细胞肺癌临床疗效[J].临床军医杂志,2018,46(3):298-299,301.
[16]谢亚琳,梁继珍,苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报,2015,35(03):446-449.
[17]Sequist Lv,Yang JC,Yamamoto N,et al.PhaseⅢstudy of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation[J].J Clin Oncol,2013,31(27):3327-34.
[18]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15(2):213-22.
[19]Mok TS,Wu YL,Ahn MJ,et al.Osimertinib or platinum-pemetrexed in EGFR T790-positive lung cancer[J].N Engl J Med,2017,376(7):629-40.
[20]Yu HA,Riely GJ,Lovly CM.Therapeutic strategies utilized in the setting of acquired resistance to EGFR turosine kinase inhibi-tors[J].Clin Cancer Res,2014,20(23):5898-5907.
[21]李静,武新虎,朱锡旭.非小细胞肺癌EGFR-TKI耐药机制及耐药后治疗策略[J].医学研究生学报,2013,26(8):859-863.
[22]Robinson R,Viviano SR,Criscione JM,et al.Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration:the role of size for intraocular drug delivery[J].ACS Nano,2011,5(6):4392-4400.
[23]Shukuya T,Takahashi T,Naito T,et al.Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure[J].Lung Cancer,2011,74(3):457-461.
[24]Man Zou,Shu Xia,Liang Zhuang,et al.Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinaseinhibitors in the H1975 lung cancer cell line harboring T790M mutation[J].International Journal of Oncology,2013,42(6).
[25]Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3signaling[J].Scien ce,2007,316(5827):1039-1043.
[26]Chen KL,Lin CC,Cho YT,et al.Comparison of Skin toxic Effects Associated With Gefitinib,Erlotinib,or Afatinib Treatment for Non-Amsll Cell Lung Cancer[J].JAMA Dermatol,2016,152(3):340-342.
[27]高佩,王云启.肺复康方联合分子靶药治疗非小细胞肺癌30例临床观察[J].湖南中医杂志,2016(9):5-8.
[28]王秀改,李平.李平教授从肺论治EGFR-TKI所致皮疹的经验[J]中医药学报,2014(2):108-110.
[29]胡正国,庞德湘.庞德湘教授治疗肺癌靶向治疗所致腹泻经验总结[J].广西中药大学学报,2014(4):18-20.
[30]许海柱,张璇,孙建率.EGFR-TKIs联合中医药治疗晚期非小细胞肺癌的多因素分析[J].时珍国医国药,2017,28(9):2156-2158.
[31]王斌,田华琴,王艳杰,等.四虫散联合鸦胆子油乳治疗非小细胞肺癌脑转移临床研究[J].中医学报,2016(1):8-11.
[32]柴小妹,吴万垠,李柳宁,等.扶正抗癌方联合吉非替尼治疗PS≤2分晚期NSCLC的疗效与安全性研究[J].现代中西医结合杂志,2014,23(3):229-231,250.
[33]张璇.中医药抑制NSCLC对EGFR-TKI药物获得性耐药的研究进展[J].医学综述,2012,18(8):1222-1224.
[2]狄鸿胜.非小细胞肺癌的治疗新进展[J].吉林医学,2012,3(10):2165-2166.
[3]李新,韩峰,张小涛.等.NP方案联合同步调强放疗治疗局部晚期非小细胞肺癌的临床观察[J].中国肿瘤临床,2012,39(23):1964-1966.
[4]张力建,陈晋峰.非小细胞肺癌的综合治疗[J].中华肿瘤防治杂志,200612(23):232-4.
[5]支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,1:73-74.
[6]Ettinger DS,Wood DE,Akerley W.NCCN Guidelines Insights:Non-Small Cell Lung Cancer,Version4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-264.
[7]张妮,曾维威,张献全.培美曲塞维持治疗晚期非小细胞肺癌的Meta分析[J].中国老年学杂志,2014,34(07):1774-1776.
[8]田晓刚,王小虎.非小细胞肺癌放疗的研究进展[J].甘肃医药,2012,31(09):673-675.
[9]贺智勇,荣阳,荣根满.中晚期肺癌介入治疗的疗效分析与临床研究[J].中国医药指南,2017,15(19):138.
[10]张宁玲.肺癌分子靶向治疗分析[J].肿瘤药学,2012,2(2):151-153.
[11]Xu Y,Zhu C,Qian W,et al.Comprehensive study of mutational and clinicopathologiccharacteristicsofadenocarcinomawithlepidic pattern in surgical resected lung adenocarcinoma[J].J Cancer Res Clin Oncol,2017,143:181-186.
[12]IdbaihA,AimardJ,BoisselierB,etal.Epidermalgrowthfactor receptorextracellular domain mutations in primary glioblastoma[J].NeuropatholApp Neurobiol,2009,35(2):208-13.
[13]金静思,贺巾钊,周黎明.非小细胞肺癌分子靶向治疗药物的现状及进展[J].中国肿瘤临床,2015,42(17):881-885.
[14]梁琨,杨帆.吉非替尼一线治疗EGFR突变型非小细胞肺癌老年患者的临床研究[J].陕西医学杂志,2017,(12):1670-1671.
[15]袁刚,韩涛,刘中正,等.厄洛替尼治疗老年晚期非小细胞肺癌临床疗效[J].临床军医杂志,2018,46(3):298-299,301.
[16]谢亚琳,梁继珍,苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报,2015,35(03):446-449.
[17]Sequist Lv,Yang JC,Yamamoto N,et al.PhaseⅢstudy of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation[J].J Clin Oncol,2013,31(27):3327-34.
[18]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15(2):213-22.
[19]Mok TS,Wu YL,Ahn MJ,et al.Osimertinib or platinum-pemetrexed in EGFR T790-positive lung cancer[J].N Engl J Med,2017,376(7):629-40.
[20]Yu HA,Riely GJ,Lovly CM.Therapeutic strategies utilized in the setting of acquired resistance to EGFR turosine kinase inhibi-tors[J].Clin Cancer Res,2014,20(23):5898-5907.
[21]李静,武新虎,朱锡旭.非小细胞肺癌EGFR-TKI耐药机制及耐药后治疗策略[J].医学研究生学报,2013,26(8):859-863.
[22]Robinson R,Viviano SR,Criscione JM,et al.Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration:the role of size for intraocular drug delivery[J].ACS Nano,2011,5(6):4392-4400.
[23]Shukuya T,Takahashi T,Naito T,et al.Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure[J].Lung Cancer,2011,74(3):457-461.
[24]Man Zou,Shu Xia,Liang Zhuang,et al.Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinaseinhibitors in the H1975 lung cancer cell line harboring T790M mutation[J].International Journal of Oncology,2013,42(6).
[25]Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3signaling[J].Scien ce,2007,316(5827):1039-1043.
[26]Chen KL,Lin CC,Cho YT,et al.Comparison of Skin toxic Effects Associated With Gefitinib,Erlotinib,or Afatinib Treatment for Non-Amsll Cell Lung Cancer[J].JAMA Dermatol,2016,152(3):340-342.
[27]高佩,王云启.肺复康方联合分子靶药治疗非小细胞肺癌30例临床观察[J].湖南中医杂志,2016(9):5-8.
[28]王秀改,李平.李平教授从肺论治EGFR-TKI所致皮疹的经验[J]中医药学报,2014(2):108-110.
[29]胡正国,庞德湘.庞德湘教授治疗肺癌靶向治疗所致腹泻经验总结[J].广西中药大学学报,2014(4):18-20.
[30]许海柱,张璇,孙建率.EGFR-TKIs联合中医药治疗晚期非小细胞肺癌的多因素分析[J].时珍国医国药,2017,28(9):2156-2158.
[31]王斌,田华琴,王艳杰,等.四虫散联合鸦胆子油乳治疗非小细胞肺癌脑转移临床研究[J].中医学报,2016(1):8-11.
[32]柴小妹,吴万垠,李柳宁,等.扶正抗癌方联合吉非替尼治疗PS≤2分晚期NSCLC的疗效与安全性研究[J].现代中西医结合杂志,2014,23(3):229-231,250.
[33]张璇.中医药抑制NSCLC对EGFR-TKI药物获得性耐药的研究进展[J].医学综述,2012,18(8):1222-1224.